Diplomat Pharmacy (DPLO) Issues Earnings Results

Diplomat Pharmacy (NYSE:DPLO) announced its earnings results on Tuesday, May 7th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.26), MarketWatch Earnings reports. The company had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.17 billion. Diplomat Pharmacy had a positive return on equity of 1.38% and a negative net margin of 5.85%. The business’s quarterly revenue was down 6.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.01) EPS. Diplomat Pharmacy updated its FY19 guidance to ($0.65-0.44) EPS and its FY 2019 guidance to $-0.65–0.44 EPS.

Shares of NYSE DPLO traded up $0.04 during trading hours on Friday, reaching $4.62. The stock had a trading volume of 742,405 shares, compared to its average volume of 1,169,505. The stock has a market cap of $342.17 million, a PE ratio of 23.10 and a beta of 0.69. The company has a quick ratio of 0.66, a current ratio of 1.00 and a debt-to-equity ratio of 1.00. Diplomat Pharmacy has a fifty-two week low of $4.39 and a fifty-two week high of $28.74.

Several brokerages recently commented on DPLO. Zacks Investment Research downgraded shares of Diplomat Pharmacy from a “hold” rating to a “strong sell” rating in a report on Friday, May 10th. ValuEngine upgraded shares of Diplomat Pharmacy from a “hold” rating to a “buy” rating in a research report on Friday, May 10th. Credit Suisse Group dropped their target price on shares of Diplomat Pharmacy from $10.00 to $8.00 and set a “neutral” rating for the company in a research report on Tuesday, April 2nd. Guggenheim assumed coverage on shares of Diplomat Pharmacy in a research report on Wednesday, April 17th. They issued a “neutral” rating and a $6.00 target price for the company. Finally, Morgan Stanley dropped their target price on shares of Diplomat Pharmacy from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Monday, March 18th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $10.25.

Several hedge funds and other institutional investors have recently made changes to their positions in DPLO. Bank of New York Mellon Corp boosted its position in shares of Diplomat Pharmacy by 97.5% in the 4th quarter. Bank of New York Mellon Corp now owns 1,682,590 shares of the company’s stock valued at $22,648,000 after purchasing an additional 830,436 shares during the period. Advisory Services Network LLC acquired a new stake in Diplomat Pharmacy during the 4th quarter worth approximately $8,062,000. FMR LLC lifted its position in Diplomat Pharmacy by 61.8% during the 4th quarter. FMR LLC now owns 1,189,312 shares of the company’s stock worth $16,008,000 after acquiring an additional 454,112 shares during the period. Stephens Inc. AR acquired a new stake in Diplomat Pharmacy during the 1st quarter worth approximately $2,424,000. Finally, Dimensional Fund Advisors LP lifted its position in Diplomat Pharmacy by 22.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,128,358 shares of the company’s stock worth $28,650,000 after acquiring an additional 395,246 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Rockland Register and is the sole property of of Rockland Register. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://rocklandregister.com/2019/06/01/diplomat-pharmacy-dplo-posts-earnings-results.html.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Recommended Story: Straddles

Earnings History for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.